Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations

BACKGROUND: Osimertinib belongs to the third-generation epidermal growth factor receptor tyrosine kinase inhibitor that has shown positive effects in treating lung adenocarcinoma cancer. However, the subsequent resistance to Osimertinib has become a clinical challenge. CASE PRESENTATION: We present...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiu, Weigang, Zhang, Qianqian, Yu, Min, Huang, Yin, Huang, Meijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100222/
https://www.ncbi.nlm.nih.gov/pubmed/33968729
http://dx.doi.org/10.3389/fonc.2021.630256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100222/
https://www.ncbi.nlm.nih.gov/pubmed/33968729
http://dx.doi.org/10.3389/fonc.2021.630256

Ejemplares similares